Joint research with the Cancer Institute on liquid biopsy
First written in FY2018. 10 of 11 entries say "Restated". Latest entry: FY2023-Q3.
1 other company's latest entry also says "Restated".
- FY2023-Q3RestatedAnnual report
「CPM is also conducting joint research with the Cancer Institute on neoantigen prediction algorithms, including a fully automated pipeline.」
Joint research with the Cancer Institute on neoantigen prediction algorithms and liquid biopsy remains ongoing. - FY2023-Q1RestatedAnnual report
「CPM is also conducting joint research with the Cancer Institute on neoantigen prediction algorithms, including a fully automated pipeline.」
Joint research with the Cancer Institute on neoantigen prediction algorithms and liquid biopsy remains ongoing. - FY2022-Q3RestatedAnnual report
「CPM is conducting joint research with the Cancer Institute on the detection of cancer gene mutations using liquid biopsy.」
Joint research with the Cancer Institute on liquid biopsy, neoantigen prediction algorithms and other areas remains ongoing. - FY2022-Q1RestatedAnnual report
「CPM is conducting joint research with the Cancer Institute on the detection of cancer gene mutations using liquid biopsy.」
Joint research with the Cancer Institute on liquid biopsy, neoantigen prediction algorithms and other areas remains ongoing. - FY2021-Q3RestatedAnnual report
「CPM is conducting joint research with the Cancer Institute on the detection of cancer gene mutations using liquid biopsy.」
Joint research with the Cancer Institute on liquid biopsy, neoantigen prediction algorithms and other areas remains ongoing. - FY2021-Q2RestatedAnnual report
「CPM is conducting joint research with the Cancer Institute on the detection of cancer gene mutations using liquid biopsy.」
Joint research with the Cancer Institute on liquid biopsy, neoantigen prediction algorithms and other areas remains ongoing. - FY2021-Q1RestatedAnnual report
「CPM is conducting joint research with the Cancer Institute on the detection of cancer gene mutations using liquid biopsy.」
Joint research with the Cancer Institute on liquid biopsy, neoantigen prediction algorithms and other areas remains ongoing. - FY2020-Q3RestatedAnnual report
「CPM is conducting joint research with the Cancer Institute on the detection of cancer gene mutations using liquid biopsy.」
Joint research with the Cancer Institute on liquid biopsy, neoantigen prediction algorithms and other areas remains ongoing. - FY2020-Q2RestatedAnnual report
「CPM is conducting joint research with the Cancer Institute on the detection of cancer gene mutations using liquid biopsy.」
Joint research with the Cancer Institute on liquid biopsy, neoantigen prediction algorithms and other areas remains ongoing. - FY2020-Q1RestatedAnnual report
「CPM is conducting joint research with the Cancer Institute on the detection of cancer gene mutations using liquid biopsy.」
Joint research with the Cancer Institute on detecting genetic mutations using liquid biopsy, neoantigen prediction algorithms and other areas remains ongoing. - FY2018First statedAnnual report
「CPM is conducting joint research with the Cancer Institute on the detection of cancer gene mutations using liquid biopsy.」
The companies began joint research on the potential clinical application of liquid biopsy technology and novel gene panels for solid tumors, including research and development, screening, selection of molecularly targeted therapies and recurrence monitoring.